| Market Cap | 223.61M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -87.9M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -7.00% |
| Sales | 3.89M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -11.00% |
| Dividend | N/A | Price/Book | 13.93 | EPS next 5Y | - | 52W High Chg | -33.00% |
| Recommedations | - | Quick Ratio | 0.84 | Shares Outstanding | 21.14M | 52W Low Chg | 12.00% |
| Insider Own | 10.16% | ROA | -195.55% | Shares Float | 15.09M | Beta | 0.71 |
| Inst Own | 35.33% | ROE | -697.51% | Shares Shorted/Prior | -/- | Price | 13.25 |
| Gross Margin | 42.02% | Profit Margin | - | Avg. Volume | 356 | Target Price | - |
| Oper. Margin | -2,585.09% | Earnings Date | Aug 22 | Volume | 30 | Change | 0.00% |
Anteris Technologies Ltd, a structural heart company, engages in the designing, developing, and commercializing medical devices. The company's lead product candidate is DurAVR, a transcatheter heart valve (THV) for the treatment of aortic stenosis. It also offers ComASUR, a delivery system that provides controlled deployment and placement of the DurAVR THV with balloon-expandable delivery, which allow precise alignment of the heart's native commissures to achieve ideal valve positioning; and ADAPT, a patented anti-calcification tissue technology. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.